Catalent logo

Catalent

Stock
Stock
ISIN: US1488061029
Ticker: CTLT
US1488061029
CTLT

Price

Price

CHART BY

Frequently asked questions

What is Catalent's market capitalization?

The market capitalization of Catalent is $11.52B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Catalent?

Catalent's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.27. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Catalent's stock?

Currently, 4 analysts cover Catalent's stock, with a consensus target price of $63.50. Analyst ratings provide insights into the stock's expected performance.

What is Catalent's revenue over the trailing twelve months?

Over the trailing twelve months, Catalent reported a revenue of $4.42B.

What is the EBITDA for Catalent?

Catalent's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $645.00M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Catalent?

Catalent has a free cash flow of $99.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Catalent have, and what sector and industry does it belong to?

Catalent employs approximately 16,900 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.

What is the free float of Catalent's shares?

The free float of Catalent is 180.79M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$11.52B
EPS (TTM) 
-$2.27
Free Float 
180.79M
Revenue (TTM) 
$4.42B
EBITDA (TTM) 
$645.00M
Free Cashflow (TTM) 
$99.00M

Pricing

52W span
$42.11$63.50

Analyst Ratings

The price target is $63.50 and the stock is covered by 4 analysts.

Buy

0

Hold

4

Sell

0

Information

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Employees
16,900
Industries
Pharmaceuticals: Major
Sector
Health Care

Identifier

ISIN
US1488061029
Primary Ticker
CTLT

Knockouts

Join the conversation